ultrapharm limited
ultrapharm limited Company Information
Company Number
01833984
Next Accounts
Apr 2025
Shareholders
finsbury food group limited
Group Structure
View All
Industry
Manufacture of bread; manufacture of fresh pastry goods and cakes
Registered Address
maes-y-coed road, maes-y-coed road, cardiff, CF14 4XR
Website
www.ultrapharm.euultrapharm limited Estimated Valuation
Pomanda estimates the enterprise value of ULTRAPHARM LIMITED at £8.5m based on a Turnover of £14.1m and 0.6x industry multiple (adjusted for size and gross margin).
ultrapharm limited Estimated Valuation
Pomanda estimates the enterprise value of ULTRAPHARM LIMITED at £0 based on an EBITDA of £-336k and a 4.41x industry multiple (adjusted for size and gross margin).
ultrapharm limited Estimated Valuation
Pomanda estimates the enterprise value of ULTRAPHARM LIMITED at £0 based on Net Assets of £-63k and 2.08x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Ultrapharm Limited Overview
Ultrapharm Limited is a live company located in cardiff, CF14 4XR with a Companies House number of 01833984. It operates in the manufacture of bread sector, SIC Code 10710. Founded in July 1984, it's largest shareholder is finsbury food group limited with a 100% stake. Ultrapharm Limited is a mature, mid sized company, Pomanda has estimated its turnover at £14.1m with high growth in recent years.
Upgrade for unlimited company reports & a free credit check
Ultrapharm Limited Health Check
Pomanda's financial health check has awarded Ultrapharm Limited a 2 rating. We use a traffic light system to show it exceeds the industry average on 1 measures and has 6 areas for improvement. Company Health Check FAQs
1 Strong
5 Regular
6 Weak
Size
annual sales of £14.1m, make it in line with the average company (£15.1m)
£14.1m - Ultrapharm Limited
£15.1m - Industry AVG
Growth
3 year (CAGR) sales growth of 20%, show it is growing at a faster rate (6.7%)
20% - Ultrapharm Limited
6.7% - Industry AVG
Production
with a gross margin of 21.8%, this company has a higher cost of product (28.3%)
21.8% - Ultrapharm Limited
28.3% - Industry AVG
Profitability
an operating margin of -5.8% make it less profitable than the average company (2.9%)
-5.8% - Ultrapharm Limited
2.9% - Industry AVG
Employees
with 147 employees, this is similar to the industry average (174)
147 - Ultrapharm Limited
174 - Industry AVG
Pay Structure
on an average salary of £30.1k, the company has an equivalent pay structure (£28.3k)
£30.1k - Ultrapharm Limited
£28.3k - Industry AVG
Efficiency
resulting in sales per employee of £95.8k, this is equally as efficient (£101.5k)
£95.8k - Ultrapharm Limited
£101.5k - Industry AVG
Debtor Days
it gets paid by customers after 62 days, this is later than average (43 days)
62 days - Ultrapharm Limited
43 days - Industry AVG
Creditor Days
its suppliers are paid after 43 days, this is close to average (45 days)
43 days - Ultrapharm Limited
45 days - Industry AVG
Stock Days
it holds stock equivalent to 45 days, this is more than average (27 days)
45 days - Ultrapharm Limited
27 days - Industry AVG
Cash Balance
has cash to cover current liabilities for 1 weeks, this is less cash available to meet short term requirements (10 weeks)
1 weeks - Ultrapharm Limited
10 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 100.7%, this is a higher level of debt than the average (59.7%)
100.7% - Ultrapharm Limited
59.7% - Industry AVG
ULTRAPHARM LIMITED financials
Ultrapharm Limited's latest turnover from July 2023 is £14.1 million and the company has net assets of -£63 thousand. According to their latest financial statements, Ultrapharm Limited has 147 employees and maintains cash reserves of £278 thousand as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Jul 2023 | Jul 2022 | Jun 2021 | Jun 2020 | Jun 2019 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 14,081,000 | 12,503,000 | 8,562,000 | 8,090,000 | 15,138,000 | 19,503,363 | 14,453,138 | 6,384,929 | ||||||
| Other Income Or Grants | ||||||||||||||
| Cost Of Sales | 11,014,000 | 8,953,000 | 6,271,000 | 6,210,000 | 12,297,000 | 14,210,444 | 10,221,199 | 3,824,653 | ||||||
| Gross Profit | 3,067,000 | 3,550,000 | 2,291,000 | 1,880,000 | 2,841,000 | 5,292,919 | 4,231,939 | 2,560,276 | ||||||
| Admin Expenses | 3,888,000 | 3,620,000 | 2,816,000 | 2,478,000 | 2,896,000 | 4,319,286 | 3,977,524 | 2,105,591 | ||||||
| Operating Profit | -821,000 | -70,000 | -525,000 | -598,000 | -55,000 | 973,633 | 254,415 | 454,685 | ||||||
| Interest Payable | 203,000 | 55,000 | 33,000 | 6,000 | 43,000 | 129,251 | 75,007 | 2,267 | ||||||
| Interest Receivable | 16 | 397 | 218 | |||||||||||
| Pre-Tax Profit | -1,024,000 | -125,000 | -558,000 | -604,000 | -98,000 | 844,398 | 179,805 | 452,636 | ||||||
| Tax | -32,000 | -171,000 | -52,000 | -1,000 | -9,000 | -135,588 | -31,950 | |||||||
| Profit After Tax | -1,056,000 | -296,000 | -610,000 | -605,000 | -107,000 | 708,810 | 147,855 | 452,636 | ||||||
| Dividends Paid | ||||||||||||||
| Retained Profit | -1,056,000 | -296,000 | -610,000 | -605,000 | -107,000 | 708,810 | 147,855 | 452,636 | ||||||
| Employee Costs | 4,420,000 | 3,833,000 | 2,681,000 | 2,649,000 | 3,887,000 | 3,523,279 | 2,493,321 | |||||||
| Number Of Employees | 147 | 131 | 95 | 95 | 100 | 234 | 177 | 59 | ||||||
| EBITDA* | -336,000 | 312,000 | -200,000 | -278,000 | 297,000 | 1,617,796 | 639,808 | 675,986 |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Jul 2023 | Jul 2022 | Jun 2021 | Jun 2020 | Jun 2019 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 3,883,000 | 3,899,000 | 3,063,000 | 2,473,000 | 2,593,000 | 5,822,876 | 5,900,743 | 1,049,277 | 1,041,463 | 660,100 | 618,778 | 709,944 | 762,847 | 1,053,354 |
| Intangible Assets | ||||||||||||||
| Investments & Other | 619,000 | 619,000 | 619,000 | 619,000 | 619,000 | 91,615 | 91,615 | 91,615 | 91,615 | 91,615 | 91,615 | 91,615 | ||
| Debtors (Due After 1 year) | ||||||||||||||
| Total Fixed Assets | 4,502,000 | 4,518,000 | 3,682,000 | 3,092,000 | 3,212,000 | 5,822,876 | 5,900,743 | 1,140,892 | 1,133,078 | 751,715 | 710,393 | 801,559 | 854,462 | 1,144,969 |
| Stock & work in progress | 1,359,000 | 1,263,000 | 660,000 | 672,000 | 474,000 | 1,609,328 | 1,379,918 | 358,007 | 376,792 | 275,009 | 198,854 | 197,837 | 256,377 | 273,000 |
| Trade Debtors | 2,420,000 | 1,903,000 | 985,000 | 326,000 | 704,000 | 2,207,100 | 2,407,045 | 846,201 | 794,390 | 385,229 | 533,522 | 414,150 | 483,448 | 460,706 |
| Group Debtors | 85,000 | 82,000 | 153,000 | 349,000 | ||||||||||
| Misc Debtors | 266,000 | 397,000 | 256,000 | 204,000 | 160,000 | 447,834 | 429,602 | 191,293 | ||||||
| Cash | 278,000 | 1,000 | 1,000 | 354,000 | 182,000 | 664,391 | 395,708 | 505,642 | 216,009 | 490,520 | 75,665 | 40,790 | 132,036 | 80,464 |
| misc current assets | ||||||||||||||
| total current assets | 4,408,000 | 3,646,000 | 1,902,000 | 1,709,000 | 1,869,000 | 4,928,653 | 4,612,273 | 1,901,143 | 1,387,191 | 1,150,758 | 808,041 | 652,777 | 871,861 | 814,170 |
| total assets | 8,910,000 | 8,164,000 | 5,584,000 | 4,801,000 | 5,081,000 | 10,751,529 | 10,513,016 | 3,042,035 | 2,520,269 | 1,902,473 | 1,518,434 | 1,454,336 | 1,726,323 | 1,959,139 |
| Bank overdraft | 2,973,000 | 1,082,000 | 876,000 | 819,207 | 752,979 | |||||||||
| Bank loan | ||||||||||||||
| Trade Creditors | 1,321,000 | 1,729,000 | 1,161,000 | 518,000 | 857,000 | 3,269,562 | 3,791,395 | 907,136 | 913,427 | 791,181 | 508,032 | 635,212 | 443,472 | 726,274 |
| Group/Directors Accounts | 6,565,000 | 1,133,000 | 1,034,000 | 1,091,000 | 1,223,000 | 18,144 | 45,546 | |||||||
| other short term finances | ||||||||||||||
| hp & lease commitments | 44,000 | 1,000 | 30,000 | 107,000 | 374,332 | 306,688 | ||||||||
| other current liabilities | 518,000 | 1,011,000 | 863,000 | 284,000 | 316,000 | 315,319 | 349,527 | 191,581 | ||||||
| total current liabilities | 8,448,000 | 6,846,000 | 4,141,000 | 2,799,000 | 2,503,000 | 4,796,564 | 5,246,135 | 1,098,717 | 913,427 | 791,181 | 508,032 | 635,212 | 443,472 | 726,274 |
| loans | 1,316,700 | 1,236,132 | ||||||||||||
| hp & lease commitments | 168,000 | 1,000 | 22,000 | 694,261 | 763,027 | |||||||||
| Accruals and Deferred Income | ||||||||||||||
| other liabilities | 11,761 | 127,921 | 145,862 | 131,386 | 190,917 | 209,349 | ||||||||
| provisions | 357,000 | 325,000 | 154,000 | 102,000 | 52,000 | 134,864 | 9,988 | |||||||
| total long term liabilities | 525,000 | 325,000 | 154,000 | 103,000 | 74,000 | 2,145,825 | 2,009,147 | 11,761 | 127,921 | 145,862 | 131,386 | 190,917 | 209,349 | |
| total liabilities | 8,973,000 | 7,171,000 | 4,295,000 | 2,902,000 | 2,577,000 | 6,942,389 | 7,255,282 | 1,110,478 | 1,041,348 | 791,181 | 653,894 | 766,598 | 634,389 | 935,623 |
| net assets | -63,000 | 993,000 | 1,289,000 | 1,899,000 | 2,504,000 | 3,809,140 | 3,257,734 | 1,931,557 | 1,478,921 | 1,111,292 | 864,540 | 687,738 | 1,091,934 | 1,023,516 |
| total shareholders funds | -63,000 | 993,000 | 1,289,000 | 1,899,000 | 2,504,000 | 3,809,140 | 3,257,734 | 1,931,557 | 1,478,921 | 1,111,292 | 864,540 | 687,738 | 1,091,934 | 1,023,516 |
| Jul 2023 | Jul 2022 | Jun 2021 | Jun 2020 | Jun 2019 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||||||||
| Operating Profit | -821,000 | -70,000 | -525,000 | -598,000 | -55,000 | 973,633 | 254,415 | 454,685 | ||||||
| Depreciation | 485,000 | 382,000 | 325,000 | 320,000 | 352,000 | 644,163 | 385,393 | 221,301 | 212,580 | 125,091 | 103,696 | 124,566 | 89,960 | 13,725 |
| Amortisation | ||||||||||||||
| Tax | -32,000 | -171,000 | -52,000 | -1,000 | -9,000 | -135,588 | -31,950 | |||||||
| Stock | 96,000 | 603,000 | -12,000 | 198,000 | 474,000 | 229,410 | 1,021,911 | -18,785 | 101,783 | 76,155 | 1,017 | -58,540 | -16,623 | 273,000 |
| Debtors | 389,000 | 1,141,000 | 558,000 | -530,000 | 1,213,000 | -181,713 | 1,799,153 | 243,104 | 409,161 | -148,293 | 119,372 | -69,298 | 22,742 | 460,706 |
| Creditors | -408,000 | 568,000 | 643,000 | -339,000 | 857,000 | -521,833 | 2,884,259 | -6,291 | 122,246 | 283,149 | -127,180 | 191,740 | -282,802 | 726,274 |
| Accruals and Deferred Income | -493,000 | 148,000 | 579,000 | -32,000 | 316,000 | -34,208 | 157,946 | 191,581 | ||||||
| Deferred Taxes & Provisions | 32,000 | 171,000 | 52,000 | 50,000 | 52,000 | 124,876 | 9,988 | |||||||
| Cash flow from operations | -1,722,000 | -716,000 | 476,000 | -268,000 | -174,000 | 1,003,346 | 838,987 | 636,957 | ||||||
| Investing Activities | ||||||||||||||
| capital expenditure | -612,933 | -4,452,523 | ||||||||||||
| Change in Investments | 619,000 | -91,615 | 91,615 | |||||||||||
| cash flow from investments | -612,933 | -4,360,908 | ||||||||||||
| Financing Activities | ||||||||||||||
| Bank loans | ||||||||||||||
| Group/Directors Accounts | 5,432,000 | 99,000 | -57,000 | -132,000 | 1,223,000 | -27,402 | 45,546 | |||||||
| Other Short Term Loans | ||||||||||||||
| Long term loans | 80,568 | 1,236,132 | ||||||||||||
| Hire Purchase and Lease Commitments | 212,000 | -1,000 | -30,000 | -98,000 | 129,000 | -1,122 | 1,069,715 | |||||||
| other long term liabilities | -11,761 | -116,160 | 127,921 | -145,862 | 14,476 | -59,531 | -18,432 | 209,349 | ||||||
| share issue | ||||||||||||||
| interest | -203,000 | -55,000 | -33,000 | -6,000 | -43,000 | -129,235 | -74,610 | -2,049 | ||||||
| cash flow from financing | 5,441,000 | 43,000 | -120,000 | -236,000 | 3,920,000 | -234,595 | 3,443,344 | -118,209 | ||||||
| cash and cash equivalents | ||||||||||||||
| cash | 277,000 | -353,000 | 172,000 | 182,000 | 268,683 | -109,934 | 289,633 | -274,511 | 414,855 | 34,875 | -91,246 | 51,572 | 80,464 | |
| overdraft | -2,973,000 | 1,891,000 | 206,000 | 876,000 | 66,228 | 752,979 | ||||||||
| change in cash | 3,250,000 | -1,891,000 | -559,000 | -704,000 | 182,000 | 202,455 | -862,913 | 289,633 | -274,511 | 414,855 | 34,875 | -91,246 | 51,572 | 80,464 |
ultrapharm limited Credit Report and Business Information
Ultrapharm Limited Competitor Analysis
Perform a competitor analysis for ultrapharm limited by selecting its closest rivals, whether from the MANUFACTURING sector, other mid companies, companies in CF14 area or any other competitors across 12 key performance metrics.
ultrapharm limited Ownership
ULTRAPHARM LIMITED group structure
Ultrapharm Limited has 1 subsidiary company.
Ultimate parent company
FRISBEE BIDCO LTD
#0157495
2 parents
ULTRAPHARM LIMITED
01833984
1 subsidiary
ultrapharm limited directors
Ultrapharm Limited currently has 3 directors. The longest serving directors include Mr Stephen Boyd (Aug 2018) and Mr John Duffy (Aug 2018).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Mr Stephen Boyd | United Kingdom | 63 years | Aug 2018 | - | Director |
| Mr John Duffy | United Kingdom | 60 years | Aug 2018 | - | Director |
| Mr Steven Hill | United Kingdom | 42 years | Dec 2023 | - | Director |
P&L
July 2023turnover
14.1m
+13%
operating profit
-821k
+1073%
gross margin
21.8%
-23.29%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
July 2023net assets
-63k
-1.06%
total assets
8.9m
+0.09%
cash
278k
+277%
net assets
Total assets minus all liabilities
ultrapharm limited company details
company number
01833984
Type
Private limited with Share Capital
industry
10710 - Manufacture of bread; manufacture of fresh pastry goods and cakes
incorporation date
July 1984
age
41
incorporated
UK
ultimate parent company
accounts
Full Accounts
last accounts submitted
July 2023
previous names
N/A
accountant
-
auditor
PRICEWATERHOUSECOOPERS LLP
address
maes-y-coed road, maes-y-coed road, cardiff, CF14 4XR
Bank
HSBC BANK PLC
Legal Advisor
-
ultrapharm limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We found 9 charges/mortgages relating to ultrapharm limited. Currently there are 2 open charges and 7 have been satisfied in the past.
ultrapharm limited Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for ULTRAPHARM LIMITED. This can take several minutes, an email will notify you when this has completed.
ultrapharm limited Companies House Filings - See Documents
| date | description | view/download |
|---|
